Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cel-Sci Corp (AMEX:CVM) (was HIV) -- Ignore unavailable to you. Want to Upgrade?

To: fmrick who wrote (2716)	9/29/1999 11:02:00 AM
From: Jerry A. Balcolm	Respond to of 2836

Cel-Sci will no doubt retain royalty rights for every application found for L.E.A.P.S., not to mention having the right to use it themselves. I think MULTIKINE might be bigger than any of us could imagine. Remember, we selected Head and Neck Cancer first because it is so devastating and there is only a 50% survival rate. Other cancers are more survivable with current treatment, but how many of them will benefit from Multikine?? Quite a few I think. But it all remains to be seen. I would say we have the upper hand despite the fact we are not approved yet. Key is the non-toxicity of our product vs the competition. Who will win? Only time will tell. Jerry.

To: fmrick who wrote (2716)	9/29/1999 11:10:00 AM
From: Toni Wheeler	Read Replies (1) \| Respond to of 2836

I don't think it is a matter of which is worth more at this point. I saw this only this morning ... and it serves to REenforce the absolute desperate necessity to find the solution: HIV : CEL-SCI CORP (AMEX) All Headlines HEALTH INDUSTRY NEWS DIGEST - September 27 NEW YORK, Sept 27 (Reuters) - Once buoyed by findings that drug cocktails can hold back the AIDS virus, researchers now say they are dismayed by a growing number of reports that these regimens are starting to fail. Patients are reporting toxic side-effects from the dozens of pills they must take to stay alive and healthy, and even those who stick to the difficult dosing schedules often are finding that they just do not work after a while, experts say. Other top pharmaceutical and health care related stories as of 1245 EDT/1645 GMT: * AIDS outlook grim despite drugs, experts say [nN27505666] * It costs $17,600 a year to treat HIV in U.S.-study [nN27483726] * XOMA shares plummet on halt of trial for lead drug [nN27529184] * Novartis sees Starlix, Zelmac as blockbusters [n7972539] OTHER STORIES OF INTEREST: * Novartis in schizophrenia research with Maryland [nL27218945] * Novartis gets US approvability for Trileptal [nL2770443] * XOMA halts Neuprex trial in trauma patients [nN27330523] * REPEAT-Monsanto rethinking UK GM strategy -paper [nL27117517] * INTERVIEW-Campaigner sees new Monsanto strategy [nL27141962] * Monsanto may hold more talks with gene campaigners [nL27132399] * AHP settlement seeks 15-year payment plan - WSJ [nN27507653] * Osteotech sees Q3 revs, earnings below estimates [nN27510960] * Celltech in diposal talks with Ascot [nL27102095] * New study backs recombinant fertility hormone rFSH [nL27000258] * Court upholds Enzo patent in antisense technology [nN27512546] * P&U antibiotic Zyvox effective in Phase III trials [nN27514209] * Orthofix wins FDA OK to test bone fusion device [nN27512453] * Cell Pathways, Rhone-Poulenc team to fight cancer [nN27] * P&U hopes for U.S.,Europe Zyvox approval in 2000 [nL27181096] * RESEARCH ALERT - Baxter (NYSE: BAX) started [nN27510307] * RESEARCH ALERT - Pharmacyclics (NASDAQ: PCYC) target up [nN27523532] * REPEAT-CORRECTED-Novartisnot started [nL27053827] * FULL TEXT-QLT (NASDAQ: QLTI)(TSE: QLT) stock split [nN27517747] * TABLE - Hillenbrand Industries (NYSE: HB) Q3 net falls [nN27515088] FULL TEXT RELEASES: CEL-SCI Corporation Forms New Company (AMEX: HIV) [nPRN9RW015] Incyte & Schering AG Expand Genomic Database Partner[nPRN9RF046] Preliminary Phase II Clinical Results for Once-Daily[nBSW9R0116] AmBisome Phase III Study for Cryptococcal Meningitis[nBSW9R0096] Aronex Pharmaceuticals Reports Phase 3 Nyotran data [nPRN9RB041] 48-Wk Result on Pivotal Agenerase(TM)Study Presented[nPRN9RB032] Triangle Pharmaceuticals Report Coactinon(R) Phase 2[nPRN9RB033] Phar-Mor and PersonalMD.com in Strategic Partnership[nPRN9RY054] Phenotypic HIV Drug Resistance Testing Superior [nPRN9RY073] Quidel gets FDA Clearance on Influenza Point-of-Care[nPRN9RL022] *Vitatron Announces US Commercial pacemakers release [nPRN9RN016] To view the entire Reuters pharmaceutical and health care related file, double-click on [DRU] or type DRU and the F9 key.